Trial Profile
A Phase 2 Study Multi Oral Immunotherapy in Multi Food Allergic Patients to Test Tolerance M-TAX Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Food hypersensitivity
- Focus Adverse reactions
- Acronyms M-TAX
- 16 Mar 2017 Status changed from active, no longer recruiting to completed.
- 14 Jul 2016 New trial record